首页> 外国专利> Pharmaceutical compositions with resistance to soluble cea, bispecific antibodies binding cea, nucleic acid sequences encoding the antibodies and vectors and host cells comprising the nucleic acids as well as processes for the production thereof, uses thereof and corresponding kits

Pharmaceutical compositions with resistance to soluble cea, bispecific antibodies binding cea, nucleic acid sequences encoding the antibodies and vectors and host cells comprising the nucleic acids as well as processes for the production thereof, uses thereof and corresponding kits

机译：对可溶性cea具有抗性的药物组合物，与cea结合的双特异性抗体，编码抗体和载体的核酸序列以及包含该核酸的宿主细胞及其产生方法，用途和相应的试剂盒

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.

机译：本发明涉及用于治疗人的上皮肿瘤的药物组合物，所述药物组合物包含双特异性单链抗体，其具有与人CD3特异性结合的第一结合域和与人CEA特异性结合的第二结合域，其中所述第二结合结构域包含鼠单克隆抗体A5B7的CDR-H3或完整CDR-H3的至少一部分。此外，公开了生产所述药物组合物的方法以及对人CD3抗原和人CEA抗原具有特异性的特定双特异性单链抗体分子的医学/药物用途。

著录项

公开/公告号IL192277A

专利类型
公开/公告日2016-08-31

原文格式PDF
申请/专利权人 AMGEN RESEARCH (MUNICH) GMBH;
展开▼

申请/专利号IL20080192277
发明设计人
展开▼

申请日2008-06-18
分类号A61K;A61P;C07K;C12N;
国家 IL
入库时间 2022-08-21 14:26:07

相似文献

专利
外文文献
中文文献